TAVR Embolic Protection Market By Product (SENTINEL cerebral protection system, TriGUARD 3 CEP device technology): Global Opportunity Analysis and Industry Forecast, 2023-2032

List of Tables

The TAVR embolic protection market was valued for $108,782.53 thousand in 2022 and is estimated to reach $405,440.67 thousand by 2032, exhibiting a CAGR of 14% from 2023 to 2032.

Transcatheter aortic valve replacement (TAVR) embolic protection devices are specialized medical devices used during TAVR procedures. TAVR is a minimally invasive surgical technique designed to treat aortic valve stenosis, a condition in which the aortic valve in the heart becomes narrowed and obstructs blood flow. During TAVR, a new artificial valve is typically inserted into the heart through a catheter, avoiding the need for open-heart surgery.

Embolic protection devices used in TAVR procedures are specifically designed to capture and prevent the release of embolic debris (small particles or clots) that may break loose during the procedure. These embolic debris can potentially travel through the bloodstream and cause blockages or damage to other organs, including the brain, which can lead to complications such as stroke or organ damage.

The primary function of TAVR embolic protection devices is to reduce the risk of embolic events by capturing and containing any debris that might dislodge during the valve replacement procedure. These devices often consist of filters or mesh-like structures that are inserted into blood vessels to catch and trap any embolic material before it can cause harm. The growth of the TAVR embolic protection market is primarily driven by rise in incidence of cardiovascular diseases, particularly aortic valve stenosis, and the expanding geriatric population.

For instance, according to an article published in the National Library of Medicine, in 2021, aortic valve stenosis (AVS) is a common heart valve condition that becomes more prevalent with age, affecting approximately 13.2% of patients aged 75 and older. This condition is characterized by the scarring and accumulation of calcium in the valve cusp.

The growing prevalence of aortic valve stenosis in the elderly population, who often choose minimally invasive procedures such as TAVR, is a key factor driving the demand for cerebral embolic protection devices. These devices are essential for minimizing complications associated with the dislodgment of embolic debris during TAVR procedures. Thus, rise in preference for TAVR as a treatment option for aortic valve stenosis among elderly patients, who are more susceptible to cardiovascular diseases, fuels the demand for cerebral embolic protection devices and thereby drives the market growth.

However, factors that hamper the market growth include procedural complexities and high costs TAVR embolic protection devices. Utilization of these devices often requires specialized training for healthcare professionals, contributing to the challenge of implementation. In addition, the high cost associated with cerebral embolic protection devices can be a significant deterrent, particularly in regions with limited healthcare budgets.

Thus, the combination of these factors can hinder widespread adoption and market growth, necessitating efforts to simplify procedures and reduce costs to make these devices more accessible to healthcare providers and patients. Furthermore, the market is poised for potential growth, owing to a rise in initiatives undertaken by government organizations and key industry players in the development of advanced devices. These collaborative efforts aim to enhance the safety and effectiveness of cerebral embolic protection devices, which can lead to better patient outcomes.

In addition, ongoing clinical trials focused on improving these devices are expected to yield promising results. These developments are anticipated to create lucrative opportunities for the market expansion during the forecast period, as they can lead to the introduction of more innovative and efficient cerebral embolic protection solutions, meeting the evolving needs of healthcare providers and patients.

The TAVR embolic protection market is segmented into product type and region. By product type, the market is categorized into SENTINEL cerebral protection system and TriGUARD 3 CEP device technology. Region-wise, the market is analyzed across North America (the U.S. and Canada), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (Japan, China, Australia, India and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).

The key players operating in the TAVR embolic protection market are Boston Scientific Corporation, Edward Lifesciences Corporation, Filterlex Medical Ltd., Innovative Cardiovascular Solutions, LLC., Protembis GmbH, Transverse Medical Inc., Emboline, Inc., Cardioptimus ,EnCompass Technologies, Inc., and Venus MedTech HangZhou Inc. The key players have adopted strategies such as product approval, funding and clinical trials to enhance their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tavr embolic protection market analysis from 2022 to 2032 to identify the prevailing tavr embolic protection market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the tavr embolic protection market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global tavr embolic protection market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Historic market data

Key Market Segments

By Product

SENTINEL cerebral protection system
TriGUARD 3 CEP device technology

By Region

North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East And Africa

Key Market Players:

Protembis GmbH
Innovative Cardiovascular Solutions, LLC.
Filterlex Medical Ltd.
Cardioptimus
Transverse Medical Inc.
Venus MedTech HangZhou Inc.
EnCompass Technologies, Inc.
Boston Scientific Corporation
Edward Lifesciences Corporation
Emboline, Inc.

Product Code: A74414

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Reduced mortality rate
  - 3.4.1.2. Technological advancements in TAVR embolic protection devices
  - 3.4.1.3. Growing adoption of minimally invasive procedures
- 3.4.2. Restraints
  - 3.4.2.1. Product failure and recalls
  - 3.4.2.2. Procedural Complexity
- 3.4.3. Opportunities
  - 3.4.3.1. Growing focus on Research and development

CHAPTER 4: TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT

4.1. Overview
- 4.1.1. Market size and forecast
4.2. SENTINEL cerebral protection system
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. TriGUARD 3 CEP device technology
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: TAVR EMBOLIC PROTECTION MARKET, BY REGION

5.1. Overview
- 5.1.1. Market size and forecast By Region
5.2. North America
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by Product
- 5.2.3. Market size and forecast, by country
  - 5.2.3.1. U.S.
  - 5.2.3.1.1. Market size and forecast, by Product
  - 5.2.3.2. Canada
  - 5.2.3.2.1. Market size and forecast, by Product
5.3. Europe
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by Product
- 5.3.3. Market size and forecast, by country
  - 5.3.3.1. Germany
  - 5.3.3.1.1. Market size and forecast, by Product
  - 5.3.3.2. France
  - 5.3.3.2.1. Market size and forecast, by Product
  - 5.3.3.3. UK
  - 5.3.3.3.1. Market size and forecast, by Product
  - 5.3.3.4. Italy
  - 5.3.3.4.1. Market size and forecast, by Product
  - 5.3.3.5. Rest of Europe
  - 5.3.3.5.1. Market size and forecast, by Product
5.4. Asia-Pacific
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by Product
- 5.4.3. Market size and forecast, by country
  - 5.4.3.1. Japan
  - 5.4.3.1.1. Market size and forecast, by Product
  - 5.4.3.2. China
  - 5.4.3.2.1. Market size and forecast, by Product
  - 5.4.3.3. India
  - 5.4.3.3.1. Market size and forecast, by Product
  - 5.4.3.4. Australia
  - 5.4.3.4.1. Market size and forecast, by Product
  - 5.4.3.5. Rest of Asia-Pacific
  - 5.4.3.5.1. Market size and forecast, by Product
5.5. LAMEA
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by Product
- 5.5.3. Market size and forecast, by country
  - 5.5.3.1. Latin America
  - 5.5.3.1.1. Market size and forecast, by Product
  - 5.5.3.2. Middle East And Africa
  - 5.5.3.2.1. Market size and forecast, by Product

CHAPTER 6: COMPETITIVE LANDSCAPE

6.1. Introduction
6.2. Top winning strategies
6.3. Product mapping of top 10 player
6.4. Competitive dashboard
6.5. Competitive heatmap
6.6. Top player positioning, 2022

CHAPTER 7: COMPANY PROFILES

7.1. Boston Scientific Corporation
- 7.1.1. Company overview
- 7.1.2. Key executives
- 7.1.3. Company snapshot
- 7.1.4. Operating business segments
- 7.1.5. Product portfolio
- 7.1.6. Business performance
7.2. Edward Lifesciences Corporation
- 7.2.1. Company overview
- 7.2.2. Key executives
- 7.2.3. Company snapshot
- 7.2.4. Operating business segments
- 7.2.5. Product portfolio
- 7.2.6. Business performance
7.3. Filterlex Medical Ltd.
- 7.3.1. Company overview
- 7.3.2. Key executives
- 7.3.3. Company snapshot
- 7.3.4. Operating business segments
- 7.3.5. Product portfolio
- 7.3.6. Key strategic moves and developments
7.4. Protembis GmbH
- 7.4.1. Company overview
- 7.4.2. Key executives
- 7.4.3. Company snapshot
- 7.4.4. Operating business segments
- 7.4.5. Product portfolio
- 7.4.6. Key strategic moves and developments
7.5. Innovative Cardiovascular Solutions, LLC.
- 7.5.1. Company overview
- 7.5.2. Key executives
- 7.5.3. Company snapshot
- 7.5.4. Operating business segments
- 7.5.5. Product portfolio
7.6. EnCompass Technologies, Inc.
- 7.6.1. Company overview
- 7.6.2. Key executives
- 7.6.3. Company snapshot
- 7.6.4. Operating business segments
- 7.6.5. Product portfolio
- 7.6.6. Key strategic moves and developments
7.7. Transverse Medical Inc.
- 7.7.1. Company overview
- 7.7.2. Key executives
- 7.7.3. Company snapshot
- 7.7.4. Operating business segments
- 7.7.5. Product portfolio
7.8. Emboline, Inc.
- 7.8.1. Company overview
- 7.8.2. Key executives
- 7.8.3. Company snapshot
- 7.8.4. Operating business segments
- 7.8.5. Product portfolio
- 7.8.6. Key strategic moves and developments
7.9. Cardioptimus
- 7.9.1. Company overview
- 7.9.2. Key executives
- 7.9.3. Company snapshot
- 7.9.4. Operating business segments
- 7.9.5. Product portfolio
7.10. Venus MedTech HangZhou Inc.
- 7.10.1. Company overview
- 7.10.2. Key executives
- 7.10.3. Company snapshot
- 7.10.4. Operating business segments
- 7.10.5. Product portfolio
- 7.10.6. Key strategic moves and developments